Sign in Subscribe
Neurology

Boston Biomedical Research Institute Licenses Immunotherapy Technology to Combat Alzheimer's Disease

Strategic Insights

— 1 min read

The Boston Biomedical Research Institute (BBRI) has announced an agreement with Wyeth Pharmaceuticals to license its patented technology for immunotherapy to combat Alzheimer's disease. This collaboration builds on the work of senior scientist Vic Raso, whose research forms the basis for the patent applications. The deal aims to further the development of beta amyloid immunotherapy for treating Alzheimer's disease, a condition that affects millions worldwide, including over four million people in the U.S. and between six and seven million in Western Europe.

Key Takeaways:

  • The agreement between BBRI and Wyeth Pharmaceuticals will license BBRI's patented technology for immunotherapy to combat Alzheimer's disease.
  • The research was conducted by Vic Raso, a senior scientist at BBRI, and forms the basis for the patent applications.
  • Alzheimer's disease is the most common cause of dementia and the fourth leading cause of death in developed countries.
  • The disease affects over four million people in the U.S. and between six and seven million in Western Europe.
  • The prevalence of Alzheimer's disease doubles every five years beyond age 65, reaching an incidence of 1:3 in people in their 80s.
  • Under the terms of the agreement, Wyeth will pay an up-front licensing fee and patent costs, with additional milestone payments possible based on patent issuance, product approval, and royalties.
  • The specific terms of the agreement remain undisclosed.
  • This collaboration builds on the work of Elan and Wyeth with BBRI on beta amyloid immunotherapy for Alzheimer's disease.

Statistics:

  • Over four million people in the U.S. suffer from Alzheimer's disease.
  • Between six and seven million people in Western Europe suffer from Alzheimer's disease.
  • The prevalence of Alzheimer's disease doubles every five years beyond age 65.
  • Alzheimer's disease affects people at an incidence of 1:3 in their 80s.
  • Four million people in the U.S. and six to seven million in Western Europe suffer from Alzheimer's disease.

Sources:

  • NewsRx.com & NewsRx.net
  • Boston Biomedical Research Institute (BBRI)
  • Wyeth Pharmaceuticals (WYE)
  • Albert Einstein College of Medicine
  • Elan Pharmaceuticals

Read more